Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 71Carcinoma, Hepatocellular 26Prostatic Neoplasms 22Neoplasm Metastasis 19Neoplasms 18Carcinoma, Non-Small-Cell Lung 16Kidney Neoplasms 14Osteosarcoma 9Neuroendocrine Tumors 9Colorectal Neoplasms 9Carcinoma, Transitional Cell 9Carcinoma, Medullary 9Sarcoma 8Urinary Bladder Neoplasms 7Sarcoma, Ewing 7Melanoma 7Breast Neoplasms 7Brain Neoplasms 7Thyroid Neoplasms 6Ovarian Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Recurrence 5Pancreatic Neoplasms 5Lung Neoplasms 5Carcinoma 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Multiple Myeloma 4Liver Neoplasms 4Thyroid Cancer, Papillary 3

Interventions

Cisplatin 35Radiotherapy 21Magnetic Resonance Spectroscopy 19Cetuximab 17Specimen Handling 15pembrolizumab 13Carboplatin 13Radiotherapy, Intensity-Modulated 12Fluorouracil 12Docetaxel 121,2-diaminocyclohexaneplatinum II citrate 10Radiation 9Platinum 9Surgical Procedures, Operative 8Paclitaxel 8Drug Therapy 7Biopsy 7Taxes 5Surveys and Questionnaires 5toripalimab 4X-Rays 4Standard of Care 4Fluorodeoxyglucose F18 4Celecoxib 4(225)Ac-DOTA-c(RGDyK) 4cemiplimab 3Nutritional Status 3Laser Therapy 3Interviews as Topic 3Immunohistochemistry 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Laryngeal Neoplasms × cabozantinib × Clear all
NCT05136196 2026-06-05

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

National Cancer Institute (NCI)

Phase 2 Recruiting
150 enrolled
DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡